Research programme: protein degradation and immunomodulator therapy - BioTheryX

Drug Profile

Research programme: protein degradation and immunomodulator therapy - BioTheryX

Alternative Names: CKI-alpha inhibitors

Latest Information Update: 24 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer BioTheryX; Yissum Research Development Company
  • Class
  • Mechanism of Action Casein kinase I inhibitors; Casein kinase Ialpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies
  • Research Solid tumours

Most Recent Events

  • 04 May 2016 Early research in Solid tumours in USA (unspecified route) before May 2016
  • 04 May 2016 Preclinical trials in Haematological malignancies in USA (unspecified route) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top